Eyepoint Pharmaceuticals Inc (EYPT) Stock Price, Quote & News

Company Profile

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 926 5000

Fax: 617 926 5050

Website: eyepointpharma.com

Address:

480 Pleasant Street, Suite A-210, Watertown, United States

rizzato Jul. 11 at 6:50 AM

$EYPT good morning we just need a very good news now and we can see the top price again soon

0 · Reply

MasterG01 Jul. 11 at 2:37 AM

$EYPT golden cross ladies...last time we ran to 30...

2 · Reply

Quantumup Jul. 10 at 7:51 PM

Cantor reiterated $APLS Overweight/$39 after competitor $ALPMY reported preliminary IZERVAY™ figures. $OCUL $EYPT REGN $SRZN RHHBY William Blair reiterated $APLS at an Outperform rating after competitor $ALPMY hosted a business update call to provide a U.S. commercial update on Izervay. Both Seem to Question #s Cantor and William Blair said in their notes to investors:

2 · Reply

daviscupper Jul. 10 at 7:01 PM

$EYPT We are percolating and getting ready to vault into the mid teens. Cheers and glta.

0 · Reply

rizzato Jul. 10 at 5:13 PM

$EYPT low volume again nobody want to sell

0 · Reply

rizzato Jul. 10 at 4:41 PM

$EYPT I was waiting for some profit taking but for the moment is showing a big force and we will probably continue our up waiting for some news coming soon

0 · Reply

BiotechBonesaw Jul. 10 at 2:35 AM

$AKBA ho boy. This might be the best username on @Stocktwits today. @squiggleburp - prepare to defend yourself 👊 Beautiful day for biotech. Wish I had owned AKBA & $VRNA but I’m happy for my fellow @biotechbulls who did 👍 $TNXP $NUVB $EYPT look like winners to me. 👁️ All day long 🤘

2 · Reply

Dy2ski Jul. 9 at 9:56 PM

$OCUL Different valuations and shares outstanding but pretty interesting that $EYPT has been surging right along in tandem with $OCUL these past couple of months or so.

0 · Reply

ripztrip Jul. 9 at 6:09 PM

$NUVB $EYPT $CAPR $TNXP $KALV

0 · Reply

rizzato Jul. 9 at 5:48 PM

hight volume and up 16% what does it means ??????? hahahahhhahahh $EYPT

0 · Reply

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jun 12, 2025, 11:03 AM EDT - 4 weeks ago

EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

May 28, 2025, 4:01 PM EDT - 6 weeks ago

EyePoint Announces Participation at Upcoming Investor Conferences

May 27, 2025, 7:00 AM EDT - 6 weeks ago

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

May 16, 2025, 7:00 AM EDT - 2 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 7, 2025, 2:49 PM EDT - 2 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 2 months ago

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Apr 30, 2025, 7:00 AM EDT - 2 months ago

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

Mar 27, 2025, 7:00 AM EDT - 3 months ago

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 5, 2025, 2:51 PM EST - 4 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 7:00 AM EST - 4 months ago

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

Feb 26, 2025, 7:00 AM EST - 4 months ago

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

Feb 25, 2025, 7:00 AM EST - 4 months ago

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 12:39 PM EST - 5 months ago

EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival

Jan 30, 2025, 7:00 AM EST - 5 months ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Jan 8, 2025, 7:00 AM EST - 6 months ago

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.

Dec 4, 2024, 7:00 AM EST - 7 months ago

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

Nov 14, 2024, 5:04 AM EST - 8 months ago

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

Nov 4, 2024, 7:00 AM EST - 8 months ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Oct 31, 2024, 4:00 PM EDT - 9 months ago

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Oct 29, 2024, 9:47 PM EDT - 9 months ago

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

Oct 28, 2024, 5:14 PM EDT - 9 months ago

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

Oct 28, 2024, 7:00 AM EDT - 9 months ago

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

Oct 24, 2024, 7:00 AM EDT - 9 months ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

Sep 4, 2024, 7:00 AM EDT - 11 months ago

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

Aug 29, 2024, 5:35 PM EDT - 11 months ago

EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

Aug 8, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Jun 18, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

Jun 5, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

May 7, 2024, 12:50 PM EDT - 1 year ago

EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program

May 6, 2024, 9:10 AM EDT - 1 year ago

EyePoint Pharmaceuticals' stock plunges as eye treatment fails to meet trial goal

May 6, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

Apr 2, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

Mar 7, 2024, 12:29 PM EST - 1 year ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call Transcript

Mar 7, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

Mar 4, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

Feb 29, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024

Feb 21, 2024, 8:36 AM EST - 1 year ago

EyePoint Is Betting The Bank On EYP-1901

Feb 3, 2024, 4:20 PM EST - 1 year ago

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Jan 31, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 10, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema

Dec 20, 2023, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023, 7:55 AM EST - 1 year ago

EyePoint (EYPT) stock price went parabolic: brace for a pullback

Dec 4, 2023, 5:06 PM EST - 1 year ago

EyePoint announces $175 million stock offering following record surge in share price

Dec 4, 2023, 7:40 AM EST - 1 year ago

EyePoint Pharmaceuticals' stock soars 362% after company announces positive data from trial of wet AMD treatment

AMD

Dec 4, 2023, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints

Nov 1, 2023, 1:03 PM EDT - 1 year ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2023 Earnings Conference Call Transcript

Nov 1, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments

Oct 31, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023

rizzato Jul. 11 at 6:50 AM

$EYPT good morning we just need a very good news now and we can see the top price again soon

0 · Reply

MasterG01 Jul. 11 at 2:37 AM

$EYPT golden cross ladies...last time we ran to 30...

2 · Reply

Quantumup Jul. 10 at 7:51 PM

2 · Reply

daviscupper Jul. 10 at 7:01 PM

$EYPT We are percolating and getting ready to vault into the mid teens. Cheers and glta.

0 · Reply

rizzato Jul. 10 at 5:13 PM

$EYPT low volume again nobody want to sell

0 · Reply

rizzato Jul. 10 at 4:41 PM

$EYPT I was waiting for some profit taking but for the moment is showing a big force and we will probably continue our up waiting for some news coming soon

0 · Reply

BiotechBonesaw Jul. 10 at 2:35 AM

2 · Reply

Dy2ski Jul. 9 at 9:56 PM

$OCUL Different valuations and shares outstanding but pretty interesting that $EYPT has been surging right along in tandem with $OCUL these past couple of months or so.

0 · Reply

ripztrip Jul. 9 at 6:09 PM

$NUVB $EYPT $CAPR $TNXP $KALV

0 · Reply

rizzato Jul. 9 at 5:48 PM

hight volume and up 16% what does it means ??????? hahahahhhahahh $EYPT

0 · Reply

BiotechBonesaw Jul. 9 at 5:34 PM

$NUVB $EYPT $CAPR $TNXP $KALV a great day for biotech! 💊 💥 🚀 Thank you Uncle Merck!

0 · Reply

twib Jul. 9 at 5:19 PM

$EYPT 👍🤪

0 · Reply

rizzato Jul. 9 at 4:22 PM

$EYPT good news coming soon?

0 · Reply

daviscupper Jul. 9 at 3:42 PM

$EYPT We will be in the 12.50-14.00 range in the near future. Cheers.

1 · Reply

daviscupper Jul. 9 at 2:35 PM

$EYPT we are trending into earnings. Very nice.

0 · Reply

rizzato Jul. 8 at 4:18 PM

$EYPT accumulations?

2 · Reply

rizzato Jul. 7 at 2:21 PM

$EYPT up and down like a yo yo

0 · Reply

porkbullpig35 Jul. 4 at 4:28 AM

$EYPT nancy?

0 · Reply

rizzato Jul. 1 at 6:04 PM

$EYPT adding more before new top share price?

0 · Reply

rizzato Jun. 30 at 6:51 PM

$EYPT no volume at all

1 · Reply

rizzato Jun. 27 at 9:24 PM

$EYPT After Hours Volume: 416.68K is it true? nit bad at all lets see Monday

1 · Reply

rizzato Jun. 27 at 6:32 PM

$EYPT https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=EYPT

0 · Reply

Market Cap	712.88M
Revenue (ttm)	43.27M
Net Income (ttm)	-130.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-302.45%
Debt to Equity Ratio	0.00

Volume	903,300
Avg Vol	838,510
Day's Range	N/A - N/A
Shares Out	68.81M
Stochastic %K	51%
Beta	1.67
Analysts	Strong Sell
Price Target	$29.36